Findings

What do systematic reviews say?

7 questions · 7 findings · 2 reviews · Urology

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 28.6%GRADE not reported 0 · 0%Very low 1 · 14.3%Low 4 · 57.1%Moderate 0 · 0%High 0 · 0%

Vaccine treatment vs standard therapies

1‐year mortality · previously untreated patients with mRCC

Vaccine treatment showed no clear difference in 1‐year mortality compared with standard therapies (low certainty).

1 finding from 1 review

Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
RR 1.1 [0.91, 1.32]
2 studies · 1034 participants
Low

Vaccine treatment vs standard therapies

Quality of life · previously untreated patients with mRCC

The review found no eligible studies for this question.

1 finding from 1 review

Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Vaccine treatment vs standard therapies

Adverse events (grade ≥ 3) · previously untreated patients with mRCC

Vaccine treatment showed no clear difference in adverse events (grade ≥ 3) compared with standard therapies (low certainty).

1 finding from 1 review

Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
RR 1.16 [0.97, 1.39]
2 studies · 1065 participants
Low

Sunitinib vs IMA901 + sunitinib (targeted agent versus tumour vaccine + targeted agent)

Progression‐free survival · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)

It is very uncertain whether sunitinib changes progression‐free survival (absolute effect size estimates based on… compared with IMA901 + sunitinib (targeted agent versus tumour vaccine + targeted… (very low certainty).

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
HR 0.95 [0.7, 1.3]
1 study · 339 participants
Very low

Sunitinib vs IMA901 + sunitinib (targeted agent versus tumour vaccine + targeted agent)

Overall survival (absolute effect size estimates based on survival rate at 12 months) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)

Sunitinib showed no clear difference in overall survival (absolute effect size estimates based on survival… compared with IMA901 + sunitinib (targeted agent versus tumour vaccine + targeted… (low certainty).

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
HR 0.75 [0.54, 1.04]
1 study · 339 participants
Low

Sunitinib vs IMA901 + sunitinib (targeted agent versus tumour vaccine + targeted agent)

Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)

Sunitinib may leads to lower serious adverse events (Grade 3 or 4) compared with IMA901 + sunitinib (targeted agent versus tumour vaccine + targeted… (low certainty).

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
RR 0.74 [0.59, 0.95]
1 study · 334 participants
Low

Sunitinib vs IMA901 + sunitinib (targeted agent versus tumour vaccine + targeted agent)

Health‐related quality of life6 · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)

The review found no eligible studies for this question.

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found